Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PLL 001

Next Previous
Drug Profile

PLL 001

Alternative Names: PLL-001; Poly-L-lysine conjugates with acetate, butyrate, lactate, propionate

Latest Information Update: 14 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PLL Therapeutics
  • Class Acetates; Anti-inflammatories; Butyrates; Drug conjugates; Lactates; Neuroprotectants; Propionates; Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Phase I/II Amyotrophic lateral sclerosis
  • Clinical Phase Unknown Multiple sclerosis
  • Preclinical Dysbiosis; Stroke

Most Recent Events

  • 08 Apr 2025 Phase-I/II clinical trials in Amyotrophic lateral sclerosis (Treatment-experienced) in Australia (SC) (NCT06513546)
  • 07 Mar 2025 PLL 001 is available for licensing as of 07 Mar 2025. https://www.pll-therapeutics.com/clinical-trials/pipe-line/
  • 07 Mar 2025 PLL Therapeutics has patent protection for PLL 001 (PLL Therapeutics website, March 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top